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ABSTRACT. Chronic obstructive pulmonary disease (COPD) is 
characterized by progressive airflow obstruction that occurs as a result 
of the normal inflammatory process to protect against harmful irritants 
and chemicals. Another physiological regulatory process, the renin 
angiotensin system (RAS), plays an important role in the pathology 
of many diseases. Angiotensin converting enzyme (ACE) is a key 
enzyme of RAS. We investigated the frequency of the ACE gene 
I/D polymorphism in patients with COPD in Turkey. This study was 
performed on 47 unrelated patients with COPD and 64 healthy subjects. 
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DNA samples were isolated from peripheral blood, and ACE DNA 
was amplified by polymerase chain reaction. The frequencies of ACE 
genotypes were 27.7, 55.3, and 17% for DD, ID, and II in the COPD 
group, respectively, and 43.8, 43.8, and 12.4% in the control group. 
There was no statistically significant difference between groups (c2 = 
3.078; df = 2; P = 0.220). The distributions of ACE gene D alleles were 
38.2% (N = 52) in the COPD group and 61.8% (N = 84) in the control 
group; and those of I alleles were 48.8% (N = 42) in the COPD group 
and 51.2% (N = 44) in the control group. There was no statistically 
significant difference between groups for allele frequency (c2 = 2.419; 
df = 2; P = 0.120). We believe these results can be useful for large-scale 
population genetic research considering the frequency of the ACE gene 
variation in COPD patients in the Turkish population.
Key words: Angiotensin converting enzyme; Turkish population; 
Chronic obstructive pulmonary disease; Renin angiotensin system 
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a severe disease that leads to ir-
reversible obstruction of the small airways. The prevalence of COPD is rapidly increasing in 
developed countries, and it is predicted that this disease will reach the third cause of mortality 
worldwide (Marin et al., 2011). COPD is characterized by an abnormal excessive inflamma-
tory response of the lung parenchyma to inhaled irritants and toxins, and by the presence of 
systemic inflammation (Nakawah et al., 2013). Although the most important risk factor for de-
velopment of COPD is smoking, relationships between genetic and clinical features of COPD 
have been reported by multiple researchers (Busquets et al., 2007; Lee et al., 2009; Shaw et al., 
2012; Simsek et al., 2013). On the other hand, these findings have not been sufficient to clarify 
the effects of genetic markers on COPD pathogenesis.
The renin angiotensin system (RAS) plays an important physiologic role as a regulator 
of blood pressure, water homeostasis, cardiovascular remodeling, and vascular tone. Angiotensin 
converting enzyme (ACE) is a key component of RAS. The ACE insertion/deletion (I/D) gene 
polymorphism, which comprises a 287-bp fragment placed within the intron 16 region of the ACE 
gene, has been identified in different clinical cases such as acute myocardial infarction, cardiac 
hypertrophy, and failure  (Schuster et al., 1995; Holmer and Schunkert, 1996). Presence of the D 
allele has been associated with increased circulating levels of the ACE enzyme; it has been shown 
that individuals carrying the DD, ID, and II genotypes have the highest, intermediate, and lowest 
circulating levels of ACE, respectively. The ACE I/D polymorphism has been found to exhibit dif-
ferences in various ethnic and patient populations (Rigat et al., 1990; Turgut et al., 2004; Sabbagh 
et al., 2007; Li et al., 2013). It is believed that inhibition of ACE activity can, in the long term, 
provide benefits for treatment of patients with COPD through its effects on inflammation, respira-
tory function, and peripheral oxygen delivery (Forth and Montgomery, 2003).
If we consider ACE I/D polymorphic variation across populations to have benefit for 
therapeutic response or expression of COPD, it is necessary to know more about this polymor-
phism in different populations. In this study, we aimed to identify genotype and allele frequen-
cies of ACE I/D polymorphisms in patients with COPD in the Kütahya Province of Turkey. 
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MATERIAL AND METHODS
Participants
We performed this study utilizing a total of 111 subjects who were treated at the 
Department of Thoracic Medicine, Dumlupınar University, Kütahya, Turkey. Forty-seven un-
related patients with COPD were included as the patient group and 64 healthy age-matched 
subjects were included as the control group. Both groups were chosen from among the Turkish 
population. The diagnosis of COPD was established on the basis of criteria proposed by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD Guideline, 2014). All proce-
dures were explained individually to all subjects and written informed consent was obtained. 
The study protocol conformed to the ethical guidelines of the Declaration of Helsinki as re-
flected in a prior approval by the institution’s human research committee. The study was ap-
proved by the Clinical Research Ethics Committee of Afyon Kocatepe University.
Detection of ACE gene polymorphisms
DNA isolation
Blood samples were collected in tubes with ethylenediaminetetraacetic acid from all 
subjects. A total of 111 genomic DNA samples were isolated from peripheral blood leukocytes 
by a standard phenol/chloroform extraction method as previously described in detail (Turgut 
et al., 2004).
Polymerase chain reaction (PCR)
PCR was used to detect the I and D alleles in intron 16 of the ACE gene by us-
ing upstream 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and downstream 5'-GAT GTG 
GCC ATC ACA TTC GTC AGAT-3' primers. PCR was conducted in 50-µL reaction mixtures 
containing approximately 1 µg DNA sample, 5 µL 10X reaction buffer incomplete [160 mM 
NH4 2SO4, 670 mM Tris-HCL, pH 8.8, 0.1% Tween-20], 5 µL 2 mM dNTPs, 3 µL 25 mM 
MgCl2, 1 U Taq-polymerase, and 100 pmol of each primer. Amplification was performed for 
35 cycles, each cycle including denaturation, extension, and annealing temperatures of 94°C 
for 30 s, 60°C for 15 s, and 72°C for 30 s, respectively, and a final extension at 72°C for 4 min. 
An initial denaturation stage was carried out at 95°C for 2 min. The amplified fragments were 
separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining 
under ultraviolet light. The polymorphism was detected as a 490-bp fragment in the presence 
of the insertion (I allele) and as a 190-bp fragment in the presence of the deletion (D allele). 
Each sample was described as DD, ID, or II.
Statistical analysis
Statistical analyses were performed using the SPSS 16.0 software (SPSS; Chicago, 
IL, USA). All data are reported as means ± standard deviation. The chi-square test was used 
for comparison of nominal variables between groups. Statistical significance of the observed 
genotype frequencies was evaluated according to the Hardy-Weinberg rule and compared 
10430
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 13 (4): 10427-10433 (2014)
C. Ayada et al.
to the expected genotype frequencies. Hardy-Weinberg equilibrium was evaluated by the chi-
square test (Rodriguez et al., 2009). All P values < 0.05 were accepted as statistically significant.
RESULTS
The frequency of ACE I/D polymorphism genotypes in controls and patients did not 
show a significant deviation from Hardy-Weinberg equilibrium (P > 0.05) (Table 1). The 
frequencies of ACE genotypes in patients with COPD and in control subjects are shown in 
Table 2 and Figure 1. The distribution of ACE genotypes were found to be 27.7% (13) for 
DD, 55.3% (26) for ID, and 17% (8) for II in the COPD group and 43.8% (28), 43.8% (28), 
and 12.4% (8) for DD, ID, and II, respectively, in the control group. There was no statisti-
cally significant difference between groups for ACE genotype frequencies (c2 = 3.078; df = 
2; P = 0.220).
Table 1. Hardy-Weinberg equilibrium of the ACE gene I/D polymorphism.
                                         COPD                                                                  Control
 Genotype Expected Observed Expected Observed
Common homozygotes DD 14.38 13 27.56 28
Heterozygotes ID 23.23 26 28.88 28
Rare homozygotes II   9.38   8   7.56   8
                                          c2 = 0.67; P > 0.05                                     c2 = 0.06, P > 0.05 
COPD = chronic obstructive pulmonary disease.
Table 2. Genotype and allele frequencies of the ACE gene I/D polymorphism.
                                                        COPD                                                     Control
 N % N %
Genotype Frequency
ACE I/D polymorphism
   DD 13 27.7 28 43.8
   ID 26 55.3 28 43.8
   II   8 17.0   8 12.4
Total 47  64
c2 = 3.078; df = 2; P = 0.220
Allele Frequency
   ACE D allele 52 38.2 84 61.8
   ACE I allele 42 48.8 44 51.2
c2 = 2.419; df = 2; P = 0.120
COPD = chronic obstructive pulmonary disease; df = degrees of freedom.
The allele frequencies for the ACE gene in patients with COPD and in control sub-
jects are shown in Table 2. The distributions of ACE D alleles were found to be 38.2% (52) 
in the COPD group and 61.8% (84) in the control group; I alleles were found at 48.8% (42) 
and 51.2% (44) in the COPD and control groups, respectively. There was no statistically sig-
nificant difference between groups for allele frequency (c2= 2.419; df = 2; P = 0.120) (Table 
2, Figure 2).
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Figure 1. ACE genotype distributions in patients with COPD and control subjects (%). ACE, angiotensin converting 
enzyme gene; COPD, chronic obstructive pulmonary disease.
Figure 2. Frequency of ACE D and I alleles in patients with COPD and control subjects. ACE, angiotensin 
converting enzyme gene; COPD, chronic obstructive pulmonary disease.
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DISCUSSION
COPD is a highly prevalent chronic disease in the general population and is character-
ized by heterogeneous chronic airway inflammation and airway obstruction. Chronic inflam-
mation affects the whole respiratory tract, from the central to peripheral airways, via different 
inflammatory cells and mediators. Thus, responses to therapy differ between patients with 
COPD. Airway obstruction in COPD occurs progressively and irreversibly (Marin et al., 2011; 
Nakawah et al., 2013). ACE in mononuclear cells may participate in the local production or 
degradation of regulatory peptides of inflammation reactions. Some inflammatory peptides 
such as bradykinin and substance P are partially inactivated by ACE. It is known that RAS 
endocrine activities are associated with the regulation of vascular tonus and cardiac func-
tion in the body. On the other hand, RAS autocrine activities also contribute to inflammation 
reactions in tissues (Hollá et al., 1999). ACE is attractive as a candidate to play a role in the 
development of vascular pathological states (Kennon et al., 1999).
ACE polymorphic variation has been identified in association with different clinical fea-
tures of COPD, such as a disturbance in peripheral tissue oxygenation during exercise (Kanaza-
wa et al., 2002), the regulation of skeletal muscle aerobic work efficiency (Zhang et al., 2008), 
the severity of skeletal muscle weakness (Hopkinson et al., 2004), and pulmonary hypertension 
evoked by exercise challenge (Kanazawa et al., 2000). Several molecular epidemiological stud-
ies have been conducted to evaluate the risk of COPD association with the I/D polymorphism of 
the ACE gene. However, the results have been conflicting (Li et al., 2013). Busquets et al. (2007) 
have identified an association of ACE I/D genotype with smoking history and risk for developing 
COPD. On the other hand, Lee et al. (2009) reported no such association.
Recently, Simsek et al. (2013) reported a significant difference in the I/D allele fre-
quencies of the ACE gene between COPD and control groups; their study was performed in 
a Turkish population living in the eastern geographical region of Turkey. By contrast, in our 
study, we could not observe any statistically significant difference in I/D allele frequencies or 
genotypes of the ACE gene between COPD and control groups. Our study was performed in 
the Turkish population of the Kütahya Province of the Aegean geographical region of Turkey, 
which is the western part of Turkey. We know from meta-analysis that the D allele and the DD 
homozygous genotype might be significant molecular genetic markers for COPD susceptibil-
ity in Asians, but not Europeans (Li et al., 2013). This geographic phenomenon might be the 
explanation for the differences found between the previous study and our research. We note, 
however, that in the COPD group, although not statistically significant, the DD genotype and 
D allele frequencies were lower than those in the control group. If we consider that a higher 
plasma level of ACE is dependent on the DD genotype, for this population base, we can sug-
gest that the I allele might have a protective role against COPD development. In the COPD 
group, the D allele was less frequent than the I allele but not significantly. This might also 
show that the I allele might have a protective role against the development of comorbidity in 
COPD patients, which is dependent on higher plasma levels of ACE.
In conclusion, the results of the present study demonstrated that patients with COPD 
in the Kütahya Province of Turkey do not differ from healthy subjects for ACE gene I/D poly-
morphism. Our results can serve as a basis for large-scale studies on the relationship of the I/D 
genotype in COPD in the Turkish population. We also believe that investigation of genotype 
and allele frequencies related to RAS substrates such as angiotensinogen, ACE2, and angio-
tensin receptors, which might be related to COPD pathogenesis, should be investigated at a re-
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gional basis in the Turkish population. Data obtained from such studies could help to understand 
the development of COPD and its relation to population genetics, in consideration with varia-
tions in genotype frequency possibly occurring throughout the history of the Anatolian basin.
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